PL3472317T3 - Kompozycje i sposoby zmniejszania neowaskularyzacji oka - Google Patents
Kompozycje i sposoby zmniejszania neowaskularyzacji okaInfo
- Publication number
- PL3472317T3 PL3472317T3 PL17814228.7T PL17814228T PL3472317T3 PL 3472317 T3 PL3472317 T3 PL 3472317T3 PL 17814228 T PL17814228 T PL 17814228T PL 3472317 T3 PL3472317 T3 PL 3472317T3
- Authority
- PL
- Poland
- Prior art keywords
- compositions
- methods
- ocular neovascularization
- reducing ocular
- reducing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Dispersion Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662351231P | 2016-06-16 | 2016-06-16 | |
| PCT/US2017/038012 WO2017218981A2 (en) | 2016-06-16 | 2017-06-16 | Compositions and methods for reducing ocular neovascularization |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3472317T3 true PL3472317T3 (pl) | 2022-08-08 |
Family
ID=60664289
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17814228.7T PL3472317T3 (pl) | 2016-06-16 | 2017-06-16 | Kompozycje i sposoby zmniejszania neowaskularyzacji oka |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20190100582A1 (enExample) |
| EP (3) | EP4083203B1 (enExample) |
| JP (4) | JP6990667B2 (enExample) |
| KR (2) | KR20190038536A (enExample) |
| AU (2) | AU2017286680B2 (enExample) |
| CA (1) | CA3027740A1 (enExample) |
| CY (1) | CY1125152T1 (enExample) |
| DK (1) | DK3472317T3 (enExample) |
| ES (2) | ES2916344T3 (enExample) |
| HR (1) | HRP20220612T1 (enExample) |
| HU (1) | HUE059424T2 (enExample) |
| LT (1) | LT3472317T (enExample) |
| PL (1) | PL3472317T3 (enExample) |
| PT (1) | PT3472317T (enExample) |
| RS (1) | RS63282B1 (enExample) |
| SG (1) | SG11201811230RA (enExample) |
| SI (1) | SI3472317T1 (enExample) |
| SM (1) | SMT202200251T1 (enExample) |
| WO (1) | WO2017218981A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102288849B1 (ko) | 2014-03-17 | 2021-08-12 | 애드베룸 바이오테크놀로지스, 인코포레이티드 | 원추세포에서 증강된 유전자 발현을 위한 조성물 및 방법 |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| KR20170137730A (ko) | 2015-03-02 | 2017-12-13 | 애드베룸 바이오테크놀로지스, 인코포레이티드 | 망막 추상체에 폴리뉴클레오타이드의 유리체 내 전달을 위한 조성물 및 방법 |
| WO2017117464A1 (en) | 2015-12-30 | 2017-07-06 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| US11192925B2 (en) | 2016-10-19 | 2021-12-07 | Adverum Biotechnologies, Inc. | Modified AAV capsids and uses thereof |
| EP4653536A2 (en) | 2017-03-17 | 2025-11-26 | Adverum Biotechnologies, Inc. | Compositions and methods for enhanced gene expression |
| JP2021506861A (ja) | 2017-12-19 | 2021-02-22 | アコーオス インコーポレイテッド | 内耳への治療用抗体のａａｖ媒介送達 |
| BR112020017872A2 (pt) | 2018-03-02 | 2020-12-22 | Kodiak Sciences Inc. | Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos |
| EP3789489A4 (en) * | 2018-03-30 | 2022-01-05 | Tomoki Todo | ANTI-SWEEPER TYPE ONCOLYTIC VIRUS |
| BR112021021156A2 (pt) * | 2019-04-24 | 2022-02-08 | Regenxbio Inc | Terapêuticos anticorpos totalmente humanos pós-tradução modificados |
| WO2021046245A1 (en) * | 2019-09-04 | 2021-03-11 | University Of Massachusetts | Adeno-associated virus vector platform for delivery of kh902 (conbercept) and uses thereof |
| MX2022002960A (es) * | 2019-09-11 | 2022-04-06 | Adverum Biotechnologies Inc | Metodos para tratar enfermedades neovasculares oculares usando variantes de aav2 que codifican para aflibercept. |
| WO2021050094A1 (en) * | 2019-09-11 | 2021-03-18 | Adverum Biotechnologies, Inc. | Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept |
| CN114728049A (zh) * | 2019-10-07 | 2022-07-08 | 再生生物股份有限公司 | 腺相关病毒载体药物组合物和方法 |
| WO2021072265A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| US20230057380A1 (en) * | 2019-11-26 | 2023-02-23 | University Of Massachusetts | Recombinant adeno-associated virus for delivery of kh902 (conbercept) and uses thereof |
| WO2021163451A1 (en) * | 2020-02-14 | 2021-08-19 | Asklepios Biopharmaceutical, Inc. | Method of treating gene therapy associated toxicity with antibiotics |
| IL303317A (en) | 2020-12-01 | 2023-07-01 | Akouos Inc | ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA |
| CN115869425B (zh) * | 2022-12-12 | 2024-08-20 | 北京生物制品研究所有限责任公司 | 一种aav眼用注射液及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994021679A1 (en) | 1993-03-25 | 1994-09-29 | Merck & Co., Inc. | Inhibitor of vascular endothelial cell growth factor |
| JP5491511B2 (ja) * | 2008-10-07 | 2014-05-14 | ブラッコ・シュイス・ソシエテ・アノニム | 抗ポリマー抗体およびそれと結合するリポソームまたは微小胞を含むターゲッティング構築物 |
| US8663624B2 (en) * | 2010-10-06 | 2014-03-04 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
| RS66184B1 (sr) * | 2011-04-22 | 2024-12-31 | Univ California | Adeno-povezani virioni virusa sa varijantama kapsida i postupci za njihovu primenu |
| TWI775096B (zh) | 2012-05-15 | 2022-08-21 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| KR102288849B1 (ko) * | 2014-03-17 | 2021-08-12 | 애드베룸 바이오테크놀로지스, 인코포레이티드 | 원추세포에서 증강된 유전자 발현을 위한 조성물 및 방법 |
| WO2018134168A1 (en) * | 2017-01-17 | 2018-07-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of expressing a polynucleotide of interest in the cone photoreceptors |
-
2017
- 2017-06-16 AU AU2017286680A patent/AU2017286680B2/en active Active
- 2017-06-16 JP JP2018565844A patent/JP6990667B2/ja active Active
- 2017-06-16 ES ES17814228T patent/ES2916344T3/es active Active
- 2017-06-16 PT PT178142287T patent/PT3472317T/pt unknown
- 2017-06-16 SM SM20220251T patent/SMT202200251T1/it unknown
- 2017-06-16 PL PL17814228.7T patent/PL3472317T3/pl unknown
- 2017-06-16 EP EP22154859.7A patent/EP4083203B1/en active Active
- 2017-06-16 KR KR1020197001022A patent/KR20190038536A/ko not_active Abandoned
- 2017-06-16 HU HUE17814228A patent/HUE059424T2/hu unknown
- 2017-06-16 SI SI201731153T patent/SI3472317T1/sl unknown
- 2017-06-16 DK DK17814228.7T patent/DK3472317T3/da active
- 2017-06-16 LT LTEPPCT/US2017/038012T patent/LT3472317T/lt unknown
- 2017-06-16 CA CA3027740A patent/CA3027740A1/en active Pending
- 2017-06-16 ES ES22154859T patent/ES2987337T3/es active Active
- 2017-06-16 EP EP17814228.7A patent/EP3472317B1/en active Active
- 2017-06-16 WO PCT/US2017/038012 patent/WO2017218981A2/en not_active Ceased
- 2017-06-16 SG SG11201811230RA patent/SG11201811230RA/en unknown
- 2017-06-16 KR KR1020227041433A patent/KR102622823B1/ko active Active
- 2017-06-16 RS RS20220484A patent/RS63282B1/sr unknown
- 2017-06-16 EP EP24184081.8A patent/EP4427808A3/en active Pending
- 2017-06-16 HR HRP20220612TT patent/HRP20220612T1/hr unknown
-
2018
- 2018-12-12 US US16/218,350 patent/US20190100582A1/en not_active Abandoned
-
2021
- 2021-12-06 JP JP2021197648A patent/JP7384447B2/ja active Active
-
2022
- 2022-05-12 CY CY20221100331T patent/CY1125152T1/el unknown
- 2022-10-12 US US18/046,112 patent/US20230322911A1/en active Pending
-
2023
- 2023-04-13 AU AU2023202277A patent/AU2023202277A1/en active Pending
- 2023-10-05 JP JP2023173614A patent/JP7606245B2/ja active Active
-
2024
- 2024-12-06 JP JP2024213242A patent/JP2025038012A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT3472317T (lt) | Kompozicijos ir būdai, skirti neovaskuliarizacijos akyse sumažinimui | |
| IL259576A (en) | Preparations and methods for immuno-oncology | |
| IL246791A0 (en) | Compositions and methods for treating eye diseases | |
| PT3426226T (pt) | Composição oftalmológica | |
| IL260124A (en) | Compounds and methods for reducing tau expression | |
| GB201807325D0 (en) | Compositions and methods | |
| EP3094284A4 (en) | Compositions and methods for the treatment of intraocular neovascularization and/or leakage | |
| SG11201708114SA (en) | Ophthalmic compositions and methods of use therefor | |
| PL3373973T3 (pl) | Kompozycje do oczu | |
| HUE049518T2 (hu) | Készítmények és eljárások a szem megbetegedéseinek kezelésére és diagnosztizálására | |
| GB201619525D0 (en) | Ophthalmic composition | |
| IL274524A (en) | Preparations and methods for aquaculture | |
| SG11201707117SA (en) | Ophthalmic composition | |
| GB201707462D0 (en) | Ocular compositions | |
| EP3089748A4 (en) | Treating ocular neovascularization | |
| IL253220A0 (en) | Preparations and methods for the treatment of glaucoma | |
| PT3113774T (pt) | Composições de grapiprant e métodos de utilização das mesmas | |
| GB201715820D0 (en) | Compositions and methods | |
| GB201705626D0 (en) | Compositions and methods | |
| ZA201807665B (en) | Methods and compositions | |
| PT3519050T (pt) | Composições para o tratamento de condições oftálmicas | |
| PL3446682T3 (pl) | Kompozycja okulistyczna | |
| IL251588A0 (en) | Methods and preparations for increasing the potency of antifungal agents | |
| IL251590B (en) | Ophthalmic preparations | |
| EP3383369A4 (en) | Compositions and methods for ear prophylaxis and treatment |